Theta Burst Stimulation for Headaches After Traumatic Brain Injury
NCT ID: NCT04906603
Last Updated: 2021-05-28
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
NA
20 participants
INTERVENTIONAL
2019-11-01
2023-09-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Specific Aim 1. To determine the efficacy and safety of TBS for the treatment of post-traumatic headache among individuals who have sustained a mild TBI. Hypothesis 1a: TBS will be safe, well-tolerated, and reduce the number of headache days. Hypothesis 1b: TBS will improve function and quality of life outcomes.
Specific Aim 2: To determine the efficacy and safety of an accelerated time-course of TBS for the management of post-traumatic headache. Hypothesis 2a: The accelerated-time course will be safe, well-tolerated, and improve quality of life outcomes. Hypothesis 2b: The accelerated time-course will produce greater and faster improvement in headache symptoms than that reported in the literature for standard repetitive transcranial magnetic stimulation (rTMS) protocols.
Specific Aim 3: To examine the durability of treatment response to accelerated TBS during a one-month observational period. Hypothesis 3: Accelerated TBS will result in enduring treatment response of post-traumatic headache symptoms over the follow-up period.
This study will be an open-label pilot study and will enroll 20. Participants will complete four weeks of pre-intervention headache assessment via Ecological Momentary Assessment (EMA). Participants will then receive TBS intervention three times a week for four weeks. TBS will be administered in 10-minute sessions, three times per day with 20 minutes between sessions. TBS intervention will be completed using the Magstim Horizon Performance Transcranial Magnetic Stimulation (Magstim Company, Ltd.) device or the MagVenture MagPro X100 with MagOption Transcranial Magnetic Stimulation device (MagVenture, Inc.). Both devices are FDA-cleared to provide TBS for the treatment of Major Depressive Disorder and will be used off-label for this study. After TBS intervention, participants will complete an additional four weeks of EMA headache assessment and return for a one-month follow-up assessment. Participants will be assessed with multiple instruments and at multiple timepoints including interviews, questionnaires, and cognitive functioning assessments.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
TBS Headache
Theta Burst Stimulation
TBS will be administered three times per day and three days per week for four weeks (totaling 12 TBS intervention visits and 36 TBS intervention sessions). Each TBS intervention session will last approximately 10 minutes (stimulation parameters = 50 Hz, 3 pulses, 10 bursts, 10 second cycle time, 60 cycles, 1800 total pulses).
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Theta Burst Stimulation
TBS will be administered three times per day and three days per week for four weeks (totaling 12 TBS intervention visits and 36 TBS intervention sessions). Each TBS intervention session will last approximately 10 minutes (stimulation parameters = 50 Hz, 3 pulses, 10 bursts, 10 second cycle time, 60 cycles, 1800 total pulses).
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* History of mild TBI according to VA/DoD Clinical Practice Guidelines (2009) with one or more of the following criteria present after head injury:
* Loss of consciousness between 0-30 minutes
* Post-traumatic amnesia between 0-24 hours
* Alteration of consciousness/mental state up to 24 hours
* Glasgow Coma Score between 13-15 (best available score within first 24 hours)
* Post-traumatic headaches defined by International Classification for Headache Diagnosis 3rd Edition (ICHD-3) guidelines with the following criteria present:
* Headaches developing within seven days following trauma or injury to the head and/or neck
* Headaches persisting beyond three months
* Chronic daily headaches defined by clinical standards with the following criterion present:
o 15 or more headache days per month
* Men and women 18-75 years of age
* Possess a smartphone and agree to download and use the EMA application on their personal device
* Capable and willing to provide voluntary informed consent
Exclusion Criteria
* Loss of consciousness greater than 30 minutes
* Post-traumatic amnesia greater than 24 hours
* Worst Glasgow Coma Scale less than 13 within the first 24 hours unless invalidated upon review (e.g., attributable to intoxication, sedation, systemic shock)
* Abnormal structural imaging
* Current (within six months of enrollment) psychosis and mania
* Current (within one month of enrollment) substance dependence with the exclusion of opioids
* Personal history of epilepsy or seizure disorder
o Does not include seizures therapeutically-induced by ECT or identified as a single seizure event (based on the principal investigator's judgement)
* Metal particles in the eye or head (exclusive of the mouth) (e.g., shrapnel, fragments from welding or metalwork, etc.)
* Implanted medical device above the clavicle (e.g., aneurysm clips, shunts, stimulators, cochlear implants, electrodes, etc.)
* Significant neurological disorder or insult that would impact risk (based on the principal investigator's judgement and research literature)
* Current use of medications with significant potential for lowering seizure threshold
* Current benzodiazepine usage at a dose higher than 3mg of lorazepam or equivalent
* Electroconvulsive therapy (ECT) or cortical energy exposure within one month of enrollment (including participation in any other neuromodulation treatments or studies)
* Current (within one month of enrollment) participation in another interventional study that would impact the results of this research
* Inadequate communication (e.g., language barrier)
* Women who are pregnant, trying to become pregnant, or breastfeeding
* Women of childbearing age/potential who are not using a medically-accepted form of contraception when sexually active
18 Years
75 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Minnesota Office of Higher Education
OTHER_GOV
The Defense and Veterans Brain Injury Center
FED
Minneapolis Veterans Affairs Medical Center
FED
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Cristina Sophia Albott
Physician
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Minneapolis VA Health Care System
Minneapolis, Minnesota, United States
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Katrina Friedrich
Role: primary
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
VAM-19-00458
Identifier Type: -
Identifier Source: org_study_id